Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

ID#: NCT05498493

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: September 01, 2022

End Date: June 01, 2023

Contact Information:
Nadia Zubair
Caroline Goldstein
Summary: This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.

Inclusion Criteria:

- Adults ≥18 years of age

- Have a confirmed SARS-CoV-2 infection (positive PCR or are serum antibody positive [against spike protein if unvaccinated or N-capsid peptide if vaccinated])

- Speak English

- Have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain

- Endorse comfort and familiarity with technology.

Exclusion Criteria:

- No method of contact

- Major neurocognitive disorder, as defined by a score <17 on the Montreal Cognitive Assessment (MoCA)

- History of pre-COVID-19 neurologic disease (e.g., stroke)

- History of severe head injury (as defined by loss of consciousness >30 minutes)

- Ongoing substance use disorder (Mini International Neuropsychiatric Interview Version 7.0.2 [MINI] or Alcohol Use Disorders Test-Consumption [AUDIT-C] >8)

- Unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and

- Contraindication for MRI (e.g., metallic/electronic implants).

- Not involved in cognitive rehabiliation/training or daily meditative practices during study enrollment